PCSK9 inhibitors may have a role in dampening vascular inflammation to improve outcomes in severe COVID-19, a pilot study suggested. Among people with severe COVID-19 with respiratory failure and ...

WASHINGTON, DC — Treatment with inclisiran (Alnylam Pharmaceuticals/the Medicines Company), which suppresses proprotein convertase subtilisin-kexin type 9 (PCSK9) synthesis in the liver, can ...

PHILADELPHIA, PA—A novel, long-acting PCSK9 inhibitor that is injected just once every 3 months can reduce LDL-cholesterol levels by more than 50% compared with placebo in patients already taking ...

Sweden: Laroprovstat, the first oral small-molecule PCSK9 inhibitor under clinical development, demonstrated substantial LDL cholesterol–lowering effects in a phase 1 study involving treatment-naive ...

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to lower low-density lipoprotein (LDL) cholesterol and reduce cardiovascular outcomes in high-risk patients. These ...

The investigational PCSK9 inhibitor that Merck showcased recently would be more than a "me-too" drug if it ultimately wins approval, despite competition from several approved agents that slash ...

Cholesterol Compound Found in Prostate Cancer Tissue Despite widespread use of intensive statin therapy, a substantial proportion of high-risk patients with hypercholesterolemia fail to achieve ...

Older readers with bulging medicine cabinets, or parents eyeing their children’s distant futures, are not encouraged to read ...

Outcomes-based pricing arrangements for pharmaceuticals are increasingly popular. In this piece, we discuss the impact of the outcomes-based pricing arrangements proposed by Amgen on the pricing of ...

PCSK9 antibodies effectively lower the LDL-cholesterol level and, therefore, address an unmet clinical need in patients with either refractory hypercholesterolaemia, statin intolerance, or an elevated ...